Nabla Bio's latest AI model update generates de novo antibodies for GPCRs with therapeutic-grade properties within a few ...

The French biotechnology firm aims to develop therapies for various neurological conditions using its non-replicating HSV-1 vector technology.

Study in mice found transient microglial depletion, or chemokine receptor blockade, resolved immunotherapy-related cognitive impairment.

The project could eventually add more than 400 manufacturing jobs and over 1,500 construction jobs during site development.

HHS Secretary Robert F. Kennedy Jr. and biopharmas will negotiate drug prices individually. Kennedy could "propose a rulemaking plan to impose MFN pricing" if no “significant” progress has been made.

Researchers use generative AI to design synthetic enhancers that can effectively control gene expression in healthy mammalian ...

Although gene-editing and other techniques can improve the production of microbe-based biologics, AI could push these drugs ...

Ansa is accepting orders for synthetic DNA constructs ranging from 7.5 kb up to 50 kb for various applications.

Gene therapy (introducing genetic material into living cells to fix, replace, enhance, or block a faulty gene) is rapidly ...

Careful planning can make a substantial difference on your path to commercial success. Here we delve into key considerations ...

To enhance CAR T therapies, scientists are actively studying TCR signaling and T-cell exhaustion mechanisms to improve CAR T ...

Scientists identified broadly neutralizing antitoxin antibodies in blood from snake venom-exposed hyperimmune donor for ...